CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9. These antagonist candidates have potential application in autoimmune and inflammatory diseases. The paper entitled “Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9” is published in the Journal of Medicinal Chemistry (December 2008, online ahead of print) and is authored by Daqing Wang, Ph.D., Lakshmi Bhagat, Ph.D., Dong Yu, Ph.D., Fu-Gang Zhu, Ph.D., Jimmy Tang, M.S., Ekambar Kandimalla, Ph.D., and Sudhir Agrawal, D.Phil., all of Idera.
